These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35052761)

  • 1. DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
    Stefanou DT; Souliotis VL; Zakopoulou R; Liontos M; Bamias A
    Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets.
    da Costa AABA; Baiocchi G
    Semin Cancer Biol; 2021 Dec; 77():29-41. PubMed ID: 33161141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.
    Guffanti F; Alvisi MF; Caiola E; Ricci F; De Maglie M; Soldati S; Ganzinelli M; Decio A; Giavazzi R; Rulli E; Damia G
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer.
    Sriramkumar S; Matthews TD; Ghobashi AH; Miller SA; VanderVere-Carozza PS; Pawelczak KS; Nephew KP; Turchi JJ; O'Hagan HM
    Mol Cancer Res; 2020 Nov; 18(11):1699-1710. PubMed ID: 32801161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
    Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
    Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
    PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.
    Reed E
    Cancer Treat Rev; 1998 Oct; 24(5):331-44. PubMed ID: 9861196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy.
    Dungl DA; Maginn EN; Stronach EA
    Front Oncol; 2015; 5():240. PubMed ID: 26579492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Discoveries on Protein Recruitment and Regulation during the Early Stages of the DNA Damage Response Pathways.
    Waters KL; Spratt DE
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
    Damia G; Broggini M
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy Roles in the Modulation of DNA Repair Pathways.
    Gomes LR; Menck CFM; Leandro GS
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29112132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Base Excision Repair Pathway in the Processing of Complex DNA Damage Generated by Oxidative Stress and Anticancer Drugs.
    Baiken Y; Kanayeva D; Taipakova S; Groisman R; Ishchenko AA; Begimbetova D; Matkarimov B; Saparbaev M
    Front Cell Dev Biol; 2020; 8():617884. PubMed ID: 33553154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
    Sharma Saha S; Gentles L; Bradbury A; Brecht D; Robinson R; O'Donnell R; Curtin NJ; Drew Y
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
    Bowden NA
    Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms.
    Rahimian E; Amini A; Alikarami F; Pezeshki SMS; Saki N; Safa M
    DNA Repair (Amst); 2020 Dec; 96():102951. PubMed ID: 32971475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA repair and chromosomal alterations.
    Natarajan AT; Palitti F
    Mutat Res; 2008 Nov; 657(1):3-7. PubMed ID: 18801460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
    Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
    Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.